Ascend Wellness reported Q1 adjusted EPS of -$0.15 versus consensus -$0.10, missing expectations.
Revenue fell 3% QoQ to $116.9 million and 8.6% YoY to $128.0 million in Q1 2026.
Adjusted EBITDA was $26.3 million (22.5% margin), down from $30.2 million Q4, while gross profit margin rose to 46.1%.
Company added five dispensaries, now 51 locations, targets at least 60 stores by year‑end; cash fell to $60.9 million.